NasdaqGS:EXELBiotechs
Exelixis (EXEL) Stock May Be Undervalued Following FDA Review Uncertainty
Exelixis stock has already delivered a very strong 243.8% return over the past 5 years, yet valuation checks still flag it as looking cheap on several measures, so investors are weighing whether the market is still underpricing the business or already baking in much of the oncology opportunity.
A 243.8% 5 year return puts Exelixis firmly in the group of biotech stocks that have already rewarded patient holders, which naturally raises the bar for any new entry point.
Upcoming regulatory...